Real World Study of Lapatinib Among Metastatic Breast Cancer Patients

Real World Study of Lapatinib Among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study

A multicenter, retrospective, real world study of Lapatinib among Metastatic Breast Cancer (MBC) Patients in Clinical Practice.

This study collected patients used Lapatinib-base therapy among MBC, and tried to figure out if there was difference between single anti-Her2 treatment and dual anti-Her2 treatment. Furthermore, this study investigated the treatment after Lapatinib.

Inclusion Criteria:

• Patients who were treated with Lapatinib between June 2014 to June 2018.
• Patients experienced progression on prior trastuzumab-containing regimens and a taxane.
• Complete medical history was available.

Exclusion Criteria:

• Medical history was incomplete.